Comments on Medicare Drug Price Negotiation Program

Editor's note:

The authors submitted the comment letter to the Centers on Medicare and Medicaid Services on June 26, 2025.

Richard Frank, Rachel Sachs, and Christen Linke Young provide The Centers for Medicare & Medicaid Services with comments on the recent Draft Guidance for the Medicare Drug Price Negotiation Program. The comment touches on four areas of the draft guidance:

Section 30.1: Identification of Qualifying Single Source Drugs (Combination Drugs)
Section 50.1: Forward-Looking Market Data
Sections 60.3.3 and 60.3.4: Factor Adjustment
Section 130: Renegotiation

Read the full comment letter

Authors

The Brookings Institution is committed to quality, independence, and impact.
We are supported by a diverse array of funders. In line with our values and policies, each Brookings publication represents the sole views of its author(s).

Comments on Medicare Drug Price Negotiation Program

Subscribe to the Economic Studies Bulletin

Comments on Medicare Drug Price Negotiation Program

Richard G. Frank, Richard G. Frank Director - Center on Health Policy, Senior Fellow - Economic Studies Rachel Sachs, and Rachel Sachs Nonresident Fellow - Economic Studies, Center on Health Policy Christen Linke Young Christen Linke Young Visiting Fellow - Economic Studies, Center on Health Policy

Richard G. Frank, Rachel Sachs, and Christen Linke Young